Mirabella Financial Services LLP acquired a new stake in Zoetis Inc. (NYSE:ZTS – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 60,803 shares of the company’s stock, valued at approximately $11,880,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new position in Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth $33,000. Quarry LP lifted its position in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. Finally, LRI Investments LLC bought a new stake in Zoetis during the first quarter valued at about $43,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Stock Performance
NYSE ZTS opened at $176.96 on Monday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market cap of $79.84 billion, a P/E ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90. The company’s 50-day simple moving average is $185.62 and its 200 day simple moving average is $180.72.
Zoetis Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s payout ratio is presently 32.52%.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on ZTS shares. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $221.44.
Read Our Latest Report on Zoetis
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- The Risks of Owning Bonds
- 3 Strategic ETFs for Bearish Investors Post-Election
- Consumer Discretionary Stocks Explained
- Super Micro’s Stock Price Is Ready to Rebound After Market Reset
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Forces Shaping a Bullish 2025 Outlook
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.